X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (448) 448
female (386) 386
oncology (275) 275
middle aged (252) 252
carcinosarcoma - drug therapy (239) 239
aged (234) 234
index medicus (220) 220
carcinosarcoma (204) 204
carcinosarcoma - pathology (199) 199
cancer (183) 183
chemotherapy (153) 153
obstetrics & gynecology (152) 152
animals (143) 143
adult (132) 132
male (126) 126
antineoplastic combined chemotherapy protocols - therapeutic use (106) 106
uterus (106) 106
carcinosarcoma - surgery (105) 105
aged, 80 and over (103) 103
neoplasm staging (99) 99
prognosis (93) 93
uterine neoplasms - drug therapy (91) 91
rats (90) 90
tumors (87) 87
uterine neoplasms - pathology (83) 83
treatment outcome (82) 82
retrospective studies (79) 79
carcinoma (76) 76
gynecologic-oncology-group (76) 76
chemotherapy, adjuvant (65) 65
mixed mullerian tumors (65) 65
sarcoma (63) 63
combined modality therapy (60) 60
ovarian neoplasms - drug therapy (60) 60
immunohistochemistry (58) 58
therapy (58) 58
ovarian neoplasms - pathology (56) 56
cisplatin (55) 55
hematology, oncology and palliative medicine (54) 54
disease-free survival (53) 53
pathology (53) 53
carcinosarcoma - metabolism (52) 52
endometrial cancer (52) 52
mice (52) 52
uterine carcinosarcoma (52) 52
care and treatment (51) 51
antineoplastic agents - therapeutic use (49) 49
obstetrics and gynecology (49) 49
survival (49) 49
survival rate (49) 49
surgery (48) 48
ifosfamide (47) 47
carcinosarcoma - mortality (46) 46
radiotherapy (44) 44
survival analysis (44) 44
uterine neoplasms - surgery (44) 44
carcinosarcoma - therapy (43) 43
carcinosarcoma - genetics (42) 42
cisplatin - administration & dosage (42) 42
analysis (41) 41
carcinosarcoma - radiotherapy (41) 41
ovarian neoplasms - surgery (41) 41
research (39) 39
paclitaxel (38) 38
paclitaxel - administration & dosage (38) 38
breast neoplasms - drug therapy (37) 37
hysterectomy (37) 37
prognostic-factors (37) 37
ovarian cancer (36) 36
uterine sarcoma (36) 36
follow-up studies (35) 35
carcinosarcoma - diagnosis (34) 34
medicine & public health (34) 34
neoplasm recurrence, local - drug therapy (34) 34
breast cancer (33) 33
carboplatin - administration & dosage (33) 33
diagnosis (33) 33
metastasis (33) 33
stage-i (33) 33
health aspects (32) 32
phase-ii trial (32) 32
expression (31) 31
leiomyosarcoma (31) 31
radiotherapy, adjuvant (31) 31
tamoxifen (31) 31
drug therapy (30) 30
endometrial neoplasms - pathology (30) 30
fatal outcome (30) 30
mixed tumor, mullerian - drug therapy (30) 30
uterine neoplasms - radiotherapy (30) 30
carcinoma 256, walker - drug therapy (29) 29
sarcomas (29) 29
cell line, tumor (28) 28
ifosfamide - administration & dosage (28) 28
breast neoplasms - pathology (27) 27
breast-cancer (27) 27
carcinosarcoma - secondary (27) 27
mesodermal tumors (27) 27
neoplasm transplantation (27) 27
neoplasm metastasis (26) 26
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (547) 547
German (28) 28
French (11) 11
Japanese (9) 9
Russian (5) 5
Italian (2) 2
Polish (2) 2
Spanish (2) 2
Persian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Gynecologic Oncology, ISSN 0090-8258, 2014, Volume 135, Issue 2, pp. 223 - 230
Abstract Objectives Complete surgery with no macroscopic residual disease (RD) at primary (PDS) or interval debulking surgery (IDS) is the main objective of... 
Hematology, Oncology and Palliative Medicine | Obstetrics and Gynecology | Neoadjuvant chemotherapy | Number of cycles | Interval surgery | Prognosis | Epithelial ovarian cancer | Number of cycles Prognosis | SURVIVAL | TRIALS | CYTOREDUCTIVE SURGERY | METAANALYSIS | SENSITIVITY | RESIDUAL DISEASE | OBSTETRICS & GYNECOLOGY | ONCOLOGY | ADVANCED-STAGE OVARIAN | RESISTANCE | PRIMARY DEBULKING SURGERY | CARCINOMA | Adenocarcinoma - pathology | Adenocarcinoma, Mucinous - pathology | Carcinosarcoma - surgery | Humans | Middle Aged | Ovarian Neoplasms - pathology | Cystadenocarcinoma, Serous - pathology | Cystadenocarcinoma, Serous - drug therapy | Cytoreduction Surgical Procedures | Young Adult | Carcinoma, Endometrioid - surgery | Adenocarcinoma, Mucinous - surgery | Aged, 80 and over | Adult | Female | Neoadjuvant Therapy | Retrospective Studies | Adenocarcinoma, Mucinous - drug therapy | Paclitaxel - administration & dosage | Ovarian Neoplasms - drug therapy | Adenocarcinoma, Clear Cell - surgery | Carcinosarcoma - pathology | Neoplasms, Glandular and Epithelial - pathology | Reoperation | Treatment Outcome | Carcinoma, Endometrioid - drug therapy | Adenocarcinoma - drug therapy | Cystadenocarcinoma, Serous - surgery | Neoplasms, Glandular and Epithelial - surgery | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Neoplasms, Glandular and Epithelial - drug therapy | Carcinoma, Ovarian Epithelial | Adenocarcinoma, Clear Cell - pathology | Aged | Carcinosarcoma - drug therapy | Platinum Compounds - administration & dosage | Carcinoma, Endometrioid - pathology | Adenocarcinoma - surgery | Adenocarcinoma, Clear Cell - drug therapy | Cohort Studies | Ovarian Neoplasms - surgery | Cancer patients | Care and treatment | Surgery | Adjuvant treatment | Ovarian cancer | Cancer | Life Sciences
Journal Article
Cochrane database of systematic reviews (Online), ISSN 1469-493X, 2013, Volume 2, Issue 2, p. CD006812
Journal Article
Annals of Oncology, ISSN 0923-7534, 07/2016, Volume 27, Issue 7, pp. 1257 - 1266
Journal Article
European Journal of Cancer, ISSN 0959-8049, 2008, Volume 44, Issue 6, pp. 808 - 818
Journal Article
Gynecologic Oncology, ISSN 0090-8258, 2007, Volume 107, Issue 2, pp. 177 - 185
Journal Article
Proceedings of the National Academy of Sciences of the United States of America, ISSN 0027-8424, 7/2015, Volume 112, Issue 27, pp. 8409 - 8414
Journal Article
Cancer, ISSN 0008-543X, 11/2016, Volume 122, Issue 21, pp. 3297 - 3306
BACKGROUND The objective of this phase 1 and 2 trial was to identify the appropriate dose of combined carboplatin and pralatrexate for patients with recurrent,... 
pharmacokinetics | carboplatin‐pralatrexate | chemotherapy | recurrent ovarian cancer | carboplatin-pralatrexate | GYNECOLOGIC-ONCOLOGY-GROUP | ANTIFOLATE | T-CELL LYMPHOMA | TOXICITY | STAGE-III | PACLITAXEL | TRIAL | CISPLATIN | ONCOLOGY | 10-PROPARGYL-10-DEAZAAMINOPTERIN | Prognosis | Follow-Up Studies | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics | Ovarian Neoplasms - pathology | Neoplasm Recurrence, Local - drug therapy | Cystadenocarcinoma, Serous - pathology | Cystadenocarcinoma, Serous - drug therapy | Neoplasm Recurrence, Local - pathology | Tissue Distribution | Peritoneal Neoplasms - drug therapy | Adult | Female | Aminopterin - analogs & derivatives | Ovarian Neoplasms - drug therapy | Fallopian Tube Neoplasms - drug therapy | Carcinosarcoma - pathology | Peritoneal Neoplasms - pathology | Neoplasm Invasiveness | Carboplatin - administration & dosage | Fallopian Tube Neoplasms - pathology | Survival Rate | Aminopterin - administration & dosage | Carcinoma, Transitional Cell - pathology | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Carcinoma, Transitional Cell - drug therapy | Endometrial Neoplasms - drug therapy | Endometrial Neoplasms - pathology | Aged | Carcinosarcoma - drug therapy | Neoplasm Staging | Usage | Care and treatment | Cancer patients | Carboplatin | Fallopian tubes | Dosage and administration | Diagnosis | Health aspects | Cancer | Index Medicus | Abridged Index Medicus
Journal Article
PLoS ONE, ISSN 1932-6203, 01/2016, Volume 11, Issue 1, p. e0147145
There is increasing evidence that metformin, a commonly used treatment for diabetes, might have the potential to be repurposed as an economical and safe cancer... 
DIABETIC-PATIENTS | MORTALITY | SURVIVAL | INSULIN | METAANALYSIS | MULTIDISCIPLINARY SCIENCES | OVERWEIGHT | GYNECOLOGIC CANCERS | RISK | COHORT | PROLIFERATION | Metformin - therapeutic use | Prognosis | Follow-Up Studies | Endometrial Neoplasms - mortality | Adenocarcinoma, Clear Cell - mortality | Humans | Neoplasm Recurrence, Local - drug therapy | Cystadenocarcinoma, Serous - pathology | Neoplasm Recurrence, Local - mortality | Cystadenocarcinoma, Serous - drug therapy | Neoplasm Recurrence, Local - pathology | Carcinosarcoma - mortality | Female | Retrospective Studies | Carcinosarcoma - pathology | Hypoglycemic Agents - therapeutic use | Survival Rate | Cystadenocarcinoma, Serous - mortality | Endometrial Neoplasms - drug therapy | Endometrial Neoplasms - pathology | Adenocarcinoma, Clear Cell - pathology | Aged | Carcinosarcoma - drug therapy | Neoplasm Staging | Adenocarcinoma, Clear Cell - drug therapy | Care and treatment | Chemotherapy | Endometrial cancer | Analysis | Dosage and administration | Metformin | Health aspects | Cancer | Demography | Systematic review | Medical diagnosis | Epidemiology | Cancer therapies | Demographics | Cell growth | Drug dosages | Endometrium | Medical research | Statistical analysis | Gynecology | Diabetes mellitus | FDA approval | Survival | Patients | Obstetrics | Medicine | Studies | Womens health | Diabetes | Health risk assessment
Journal Article
European Journal of Cancer, ISSN 0959-8049, 2017, Volume 76, pp. 52 - 59
Abstract Drug resistance to conventional anticancer therapies is almost inevitable in patients with advanced ovarian cancer (AOC), limiting their available... 
Hematology, Oncology and Palliative Medicine | RMH prognostic score | Precision medicine | Antiangiogenics | Phase I trials | Poly(ADP-ribose) Polymerase (PARP) inhibitors | Ovarian cancer | TARGETED THERAPY | BEVACIZUMAB | FALLOPIAN-TUBE | BREAST | CHEMOTHERAPY | PIK3CA | ONCOLOGY | PERSPECTIVES | MUTATIONS | RECURRENT EPITHELIAL OVARIAN | PRIMARY PERITONEAL | Neoplasms, Cystic, Mucinous, and Serous - metabolism | Prognosis | Humans | Middle Aged | Ovarian Neoplasms - pathology | England | Antineoplastic Agents - therapeutic use | Granulosa Cell Tumor - pathology | Carcinoma, Endometrioid - metabolism | Neoplasms, Cystic, Mucinous, and Serous - genetics | Ovarian Neoplasms - genetics | Neoplasm Metastasis | Genes, BRCA2 | Adult | Female | Neoplasms, Cystic, Mucinous, and Serous - drug therapy | Granulosa Cell Tumor - drug therapy | Leukocyte Count | Membrane Proteins - metabolism | Ovarian Neoplasms - metabolism | Retrospective Studies | Genes, BRCA1 | CA-125 Antigen - metabolism | Ovarian Neoplasms - drug therapy | Carcinosarcoma - pathology | Severity of Illness Index | Hereditary Breast and Ovarian Cancer Syndrome - genetics | Carcinoma, Endometrioid - genetics | Carcinosarcoma - metabolism | Neoplasms, Cystic, Mucinous, and Serous - pathology | Adenocarcinoma, Clear Cell - metabolism | Granulosa Cell Tumor - genetics | Hemoglobins - metabolism | Survival Rate | Treatment Outcome | Carcinoma, Endometrioid - drug therapy | Drug Discovery | Granulosa Cell Tumor - metabolism | Adenocarcinoma, Clear Cell - pathology | Aged | Carcinosarcoma - drug therapy | Carcinosarcoma - genetics | Adenocarcinoma, Clear Cell - genetics | Carcinoma, Endometrioid - pathology | Clinical Trials, Phase I as Topic | Adenocarcinoma, Clear Cell - drug therapy | Serum Albumin - metabolism | Chemotherapy | Cancer patients | Clinical trials | Hemoglobin | Metastasis | Drug resistance | Sugars | Cancer | Monosaccharides
Journal Article
Journal Article